LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 324

Search options

  1. Article ; Online: No interest, no conflict.

    Stadler, Walter M

    Cancer

    2020  Volume 126, Issue 16, Page(s) 3627–3628

    MeSH term(s) Conflict of Interest/economics ; Guidelines as Topic ; Humans ; Neoplasms/economics ; Neoplasms/epidemiology ; Societies, Scientific/economics ; Societies, Scientific/ethics
    Language English
    Publishing date 2020-06-04
    Publishing country United States
    Document type Editorial
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.32995
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.146: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Management of Urothelial Bladder Cancer: Predicting the Future.

    Stadler, Walter M

    Journal of oncology practice

    2019  Volume 15, Issue 8, Page(s) 429–430

    MeSH term(s) Carcinoma, Transitional Cell ; Humans ; Urinary Bladder Neoplasms ; Urologic Neoplasms
    Language English
    Publishing date 2019-10-09
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2236338-5
    ISSN 1935-469X ; 1554-7477
    ISSN (online) 1935-469X
    ISSN 1554-7477
    DOI 10.1200/JOP.19.00419
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Optimizing the doses of cancer drugs after usual dose finding.

    Strohbehn, Garth W / Stadler, Walter M / Boonstra, Philip S / Ratain, Mark J

    Clinical trials (London, England)

    2023  , Page(s) 17407745231213882

    Abstract: Since the middle of the 20th century, oncology's dose-finding paradigm has been oriented toward identifying a drug's maximum tolerated dose, which is then carried forward into phase 2 and 3 trials and clinical practice. For most modern precision ... ...

    Abstract Since the middle of the 20th century, oncology's dose-finding paradigm has been oriented toward identifying a drug's maximum tolerated dose, which is then carried forward into phase 2 and 3 trials and clinical practice. For most modern precision medicines, however, maximum tolerated dose is far greater than the minimum dose needed to achieve maximal benefit, leading to unnecessary side effects. Regulatory change may decrease maximum tolerated dose's predominance by enforcing dose optimization of
    Language English
    Publishing date 2023-12-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 2138796-5
    ISSN 1740-7753 ; 1740-7745
    ISSN (online) 1740-7753
    ISSN 1740-7745
    DOI 10.1177/17407745231213882
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5831: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Enrollment Barriers for Molecular Targeted Trials.

    Paydary, Koosha / DeLuca, Alli / Aggarwal, Rahul / Wall, Lauren / Stadler, Walter M

    JAMA oncology

    2023  Volume 9, Issue 6, Page(s) 863–864

    MeSH term(s) Humans ; Molecular Targeted Therapy ; Neoplasms/drug therapy ; Patient Selection
    Language English
    Publishing date 2023-04-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2023.0248
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.

    Chablani, Priyanka V / Karrison, Theodore / Stadler, Walter M

    Clinical genitourinary cancer

    2022  Volume 20, Issue 6, Page(s) 510–514

    Abstract: Introduction: Dual immunotherapy (ipilimumab/nivolumab, IO/IO) and immunotherapy/tyrosine kinase inhibitor (IO/TKI) combinations (e.g. pembrolizumab/axitinib) are approved for the first-line treatment of intermediate/poor risk metastatic renal cell ... ...

    Abstract Introduction: Dual immunotherapy (ipilimumab/nivolumab, IO/IO) and immunotherapy/tyrosine kinase inhibitor (IO/TKI) combinations (e.g. pembrolizumab/axitinib) are approved for the first-line treatment of intermediate/poor risk metastatic renal cell carcinoma (RCC), but there is limited comparative data between these two options. We sought to understand how oncologists decide between IO/IO vs. IO/TKI.
    Methods: We sent a 10-question electronic survey centered on a patient scenario of intermediate/poor risk metastatic RCC to 294 academic/disease-focused and general oncologists in the US.
    Results: We received 105 responses (36% response rate): 61% (64) of providers chose IO/IO, 39% (41) chose IO/TKI. 78% (82) of oncologists were academic or disease-focused, 22% (23) were general. Academic/disease-focused oncologists were significantly more likely to choose IO/IO (56/82, 68%) than general oncologists (8/23, 35%), P = .004. Among those who chose IO/IO, the perceived main issue with IO/TKI was: long-term toxicities - 31% (20), short-term toxicities - 28% (18), less effective - 28% (18), less convenient - 8% (5). Among those who chose IO/TKI, the perceived main issue with IO/IO was: short-term toxicities - 43% (17), less effective - 28% (11), long-term toxicities - 15% (6), and risk of death - 10% (4). 88% (92) of providers would be comfortable enrolling patients into a phase III trial comparing IO/IO vs. IO/TKI. We found no associations between therapy chosen by a provider and participation as PI in a trial of IO/IO or IO/TKI, or receipt of outside funding from an IO/IO or IO/TKI company.
    Conclusion: In response to a patient scenario of intermediate/poor risk metastatic RCC, 61% of providers chose IO/IO, 39% chose IO/TKI. There was a significant association between type of practice and choice of therapy, with academic/disease-focused oncologists more likely to choose IO/IO. The majority of oncologists would be comfortable enrolling patients into a phase III trial comparing IO/IO vs. IO/TKI.
    MeSH term(s) Humans ; Carcinoma, Renal Cell/drug therapy ; Carcinoma, Renal Cell/pathology ; Immunotherapy ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/pathology ; Protein Kinase Inhibitors ; Clinical Trials, Phase III as Topic
    Chemical Substances Protein Kinase Inhibitors
    Language English
    Publishing date 2022-06-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2225121-2
    ISSN 1938-0682 ; 1558-7673
    ISSN (online) 1938-0682
    ISSN 1558-7673
    DOI 10.1016/j.clgc.2022.06.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check.

    Szmulewitz, Russell Z / Stadler, Walter M / Ratain, Mark J

    JAMA oncology

    2021  Volume 7, Issue 6, Page(s) 827–828

    MeSH term(s) Androstenes/adverse effects ; Humans
    Chemical Substances Androstenes ; abiraterone (G819A456D0)
    Language English
    Publishing date 2021-03-03
    Publishing country United States
    Document type Journal Article
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2020.8087
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Knowledge and distress in complex cancer care.

    Stadler, Walter M / Hlubocky, Fay J / Hathaway, Feighanne

    Cancer

    2021  Volume 128, Issue 7, Page(s) 1359–1360

    MeSH term(s) Genomics ; Health Literacy ; Humans ; Knowledge ; Neoplasms/therapy
    Language English
    Publishing date 2021-12-10
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.34060
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.146: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.

    Desai, Kunal B / Serritella, Anthony V / Stadler, Walter M / O'Donnell, Peter H / Sweis, Randy F / Szmulewitz, Russell Z

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2024  

    Abstract: Purpose: Majority of patients with metastatic prostate cancer who receive androgen deprivation therapy and androgen receptor (AR) signaling inhibitors progress. Activation of the glucocorticoid receptor (GR) is associated with ARSI-resistance. This ... ...

    Abstract Purpose: Majority of patients with metastatic prostate cancer who receive androgen deprivation therapy and androgen receptor (AR) signaling inhibitors progress. Activation of the glucocorticoid receptor (GR) is associated with ARSI-resistance. This single-arm phase I trial assessed safety and pharmacokinetic feasibility of combined AR antagonist (enzalutamide) and selective GR modulator (relacorilant) in metastatic castration-resistant prostate cancer (mCRPC) patients.
    Patients and methods: This was a phase I trial (NCT03674814) of relacorilant and enzalutamide in refractory mCRPC patients enrolled using 6+3 design. Enzalutamide dose was kept constant at 120 mg/day with escalating doses of relacorilant based on safety and pharmacokinetic measures in cohorts of ≥ 6 patients. Primary objective was safety and establishment of pharmacologically active doses. Secondary objectives were related to antitumor activity.
    Results: Thirty-five mCRPC patients were enrolled. Twenty-three were accrued across 3 dose cohorts in the dose escalation phase and twelve enrolled at the recommended phase 2 dose. The combination was generally well-tolerated and safe and achieved desirable enzalutamide pharmacokinetics. RP2D of 120 mg/day + 150 mg/day respectively was established. Median time on study was 2.2 months with 4 patients remaining on study for longer than 11 months. Four of twelve evaluable patients had a PSA partial response.
    Conclusions: This is the first prospective trial combining an AR antagonist and a non-steroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.
    Language English
    Publishing date 2024-03-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-3636
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Maturing of renal cancer therapeutics.

    Stadler, Walter M

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2014  Volume 32, Issue 8, Page(s) 722–724

    MeSH term(s) Angiogenesis Inhibitors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Renal Cell/drug therapy ; Female ; Humans ; Indoles/therapeutic use ; Kidney Neoplasms/drug therapy ; Male ; Niacinamide/analogs & derivatives ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Protein Kinase Inhibitors/therapeutic use ; Pyrroles/therapeutic use ; Sirolimus/analogs & derivatives ; Sirolimus/therapeutic use
    Chemical Substances Angiogenesis Inhibitors ; Indoles ; Phenylurea Compounds ; Protein Kinase Inhibitors ; Pyrroles ; Niacinamide (25X51I8RD4) ; temsirolimus (624KN6GM2T) ; sorafenib (9ZOQ3TZI87) ; sunitinib (V99T50803M) ; Sirolimus (W36ZG6FT64)
    Language English
    Publishing date 2014-03-10
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.2013.54.1748
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Optimal use of imaging to guide treatment decisions for kidney cancer.

    Stadler, Walter M

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

    2014  , Page(s) 284–287

    Abstract: Treatment monitoring for solid tumors in general and for metastatic renal cancer in particular has been dominated by assessment of tumor burden via cross-sectional imaging. This poses a special problem for the mammalian target of rapamycin and vascular ... ...

    Abstract Treatment monitoring for solid tumors in general and for metastatic renal cancer in particular has been dominated by assessment of tumor burden via cross-sectional imaging. This poses a special problem for the mammalian target of rapamycin and vascular endothelial growth factor pathway-directed agents used in this disease. The standard RECIST metrics used to categorize "response" and "progression" are arbitrary and do not adequately capture the effect of these agents. Other approaches, including use of relative RECIST measures as a continuous variable, volumetric measurements, and functional assessments, such as dynamic contrast-enhanced magnetic resonance imaging-based quantitative variables and fluorodeoxyglucose-positron emission tomography, have been proposed as alternatives, but the data do not support their routine clinical use. Even fewer data are available on the use of baseline imaging characteristics to choose a specific therapy. Therefore, until further research on imaging predictive and intermediate biomarkers matures, a combination of standard cross-sectional imaging and clinical judgment is the most pragmatic option for treatment decision making for patients with metastatic renal cancer.
    Language English
    Publishing date 2014-01-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2431126-1
    ISSN 1548-8756 ; 1548-8748
    ISSN (online) 1548-8756
    ISSN 1548-8748
    DOI 10.14694/EdBook_AM.2012.32.284
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top